Evidence map›Paper›PMID 39039289›Full record

ArticleThe EMBO journal2024

T4 DNA polymerase prevents deleterious on-target DNA damage and enhances precise CRISPR editing.

Qiaoyan Yang, Jonathan S Abebe, Michelle Mai, Gabriella Rudy, Sang Y Kim, Orrin Devinsky, Chengzu Long

Abstract read
In one paragraph

Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qiaoyan YangNYU Cardiovascular Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0002-2353-6399
Jonathan S AbebeNYU Cardiovascular Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York, NY, USA.
Michelle MaiNYU Cardiovascular Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York, NY, USA.
Gabriella RudyNYU Cardiovascular Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0002-2515-2567
Sang Y KimDepartment of Pathology, NYU Langone Health, New York, NY, USA.
Orrin DevinskyNew York University Langone Comprehensive Epilepsy Center, NYU Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0003-0044-4632
Chengzu LongNYU Cardiovascular Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York, NY, USA. Chengzu.Long@nyulangone.org.ORCID http://orcid.org/0000-0002-6236-7444

Funding

NYU Langone Health Departmental Start-Up Grant
6 · The paper itself

Abstract

Unintended on-target chromosomal alterations induced by CRISPR/Cas9 in mammalian cells are common, particularly large deletions and chromosomal translocations, and present a safety challenge for genome editing. Thus, there is still an unmet need to develop safer and more efficient editing tools. We screened diverse DNA polymerases of distinct origins and identified a T4 DNA polymerase derived from phage T4 that strongly prevents undesired on-target damage while increasing the proportion of precise 1- to 2-base-pair insertions generated during CRISPR/Cas9 editing (termed CasPlus). CasPlus induced substantially fewer on-target large deletions while increasing the efficiency of correcting common frameshift mutations in DMD and restored higher level of dystrophin expression than Cas9-alone in human cardiomyocytes. Moreover, CasPlus greatly reduced the frequency of on-target large deletions during mouse germline editing. In multiplexed guide RNAs mediating gene editing, CasPlus repressed chromosomal translocations while maintaining gene disruption efficiency that was higher or comparable to Cas9 in primary human T cells. Therefore, CasPlus offers a safer and more efficient gene editing strategy to treat pathogenic variants or to introduce genetic modifications in human applications.

Indexed as

CRISPR-Cas SystemsDNA DamageGene EditingAnimalsDNA-Directed DNA PolymeraseDystrophinHumansMiceMyocytes, CardiacRNA, Guide, CRISPR-Cas SystemsDNA-Directed DNA PolymeraseDystrophinRNA, Guide, CRISPR-Cas SystemsCRISPR/Cas9DMDDNA PolymeraseOn-target DamageT Cell

Identifiers

PMID39039289
PMCPMC11377749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.